Literature DB >> 26702067

Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome.

Sarah Walker1, Chen Wang2, Trent Walradt2, Bok Sil Hong2, Justin R Tanner3, Jonathan L Levinsohn2, Gerald Goh4, Antonio Subtil2, Stuart R Lessin5, Warren R Heymann6, Eric C Vonderheid7, Brett A King2, Richard P Lifton8, Jaehyuk Choi9.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26702067      PMCID: PMC4760095          DOI: 10.1182/blood-2015-06-654277

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  17 in total

1.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Authors:  Ramona Crescenzo; Francesco Abate; Elena Lasorsa; Fabrizio Tabbo'; Marcello Gaudiano; Nicoletta Chiesa; Filomena Di Giacomo; Elisa Spaccarotella; Luigi Barbarossa; Elisabetta Ercole; Maria Todaro; Michela Boi; Andrea Acquaviva; Elisa Ficarra; Domenico Novero; Andrea Rinaldi; Thomas Tousseyn; Andreas Rosenwald; Lukas Kenner; Lorenzo Cerroni; Alexander Tzankov; Maurilio Ponzoni; Marco Paulli; Dennis Weisenburger; Wing C Chan; Javeed Iqbal; Miguel A Piris; Alberto Zamo'; Carmela Ciardullo; Davide Rossi; Gianluca Gaidano; Stefano Pileri; Enrico Tiacci; Brunangelo Falini; Leonard D Shultz; Laurence Mevellec; Jorge E Vialard; Roberto Piva; Francesco Bertoni; Raul Rabadan; Giorgio Inghirami
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

2.  Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors.

Authors:  Johanna C Bendell; David S Hong; Howard A Burris; Aung Naing; Suzanne F Jones; Gerald Falchook; Patricia Bricmont; Agnes Elekes; Edwin P Rock; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2014-05-13       Impact factor: 3.333

Review 3.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

Review 4.  World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.

Authors:  Jason Gotlib
Journal:  Am J Hematol       Date:  2014-03       Impact factor: 10.047

5.  Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors.

Authors:  Hyokjoon Kwon; Danielle Thierry-Mieg; Jean Thierry-Mieg; Hyoung-Pyo Kim; Jangsuk Oh; Chainarong Tunyaplin; Sebastian Carotta; Colleen E Donovan; Matthew L Goldman; Prafullakumar Tailor; Keiko Ozato; David E Levy; Stephen L Nutt; Kathryn Calame; Warren J Leonard
Journal:  Immunity       Date:  2009-12-18       Impact factor: 31.745

Review 6.  Lymphocytic variant hypereosinophilic syndromes.

Authors:  Florence Roufosse; Elie Cogan; Michel Goldman
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

7.  Integration of external signaling pathways with the core transcriptional network in embryonic stem cells.

Authors:  Xi Chen; Han Xu; Ping Yuan; Fang Fang; Mikael Huss; Vinsensius B Vega; Eleanor Wong; Yuriy L Orlov; Weiwei Zhang; Jianming Jiang; Yuin-Han Loh; Hock Chuan Yeo; Zhen Xuan Yeo; Vipin Narang; Kunde Ramamoorthy Govindarajan; Bernard Leong; Atif Shahab; Yijun Ruan; Guillaume Bourque; Wing-Kin Sung; Neil D Clarke; Chia-Lin Wei; Huck-Hui Ng
Journal:  Cell       Date:  2008-06-13       Impact factor: 41.582

8.  Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling.

Authors:  Kamran Ghoreschi; Arian Laurence; Xiang-Ping Yang; Cristina M Tato; Mandy J McGeachy; Joanne E Konkel; Haydeé L Ramos; Lai Wei; Todd S Davidson; Nicolas Bouladoux; John R Grainger; Qian Chen; Yuka Kanno; Wendy T Watford; Hong-Wei Sun; Gérard Eberl; Ethan M Shevach; Yasmine Belkaid; Daniel J Cua; Wanjun Chen; John J O'Shea
Journal:  Nature       Date:  2010-10-21       Impact factor: 49.962

9.  Genomic landscape of cutaneous T cell lymphoma.

Authors:  Jaehyuk Choi; Gerald Goh; Trent Walradt; Bok S Hong; Christopher G Bunick; Kan Chen; Robert D Bjornson; Yaakov Maman; Tiffany Wang; Jesse Tordoff; Kacie Carlson; John D Overton; Kristina J Liu; Julia M Lewis; Lesley Devine; Lisa Barbarotta; Francine M Foss; Antonio Subtil; Eric C Vonderheid; Richard L Edelson; David G Schatz; Titus J Boggon; Michael Girardi; Richard P Lifton
Journal:  Nat Genet       Date:  2015-07-20       Impact factor: 38.330

10.  Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease.

Authors:  Sarah E Flanagan; Emma Haapaniemi; Mark A Russell; Richard Caswell; Hana Lango Allen; Elisa De Franco; Timothy J McDonald; Hanna Rajala; Anita Ramelius; John Barton; Kaarina Heiskanen; Tarja Heiskanen-Kosma; Merja Kajosaari; Nuala P Murphy; Tatjana Milenkovic; Mikko Seppänen; Åke Lernmark; Satu Mustjoki; Timo Otonkoski; Juha Kere; Noel G Morgan; Sian Ellard; Andrew T Hattersley
Journal:  Nat Genet       Date:  2014-07-20       Impact factor: 38.330

View more
  18 in total

1.  Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea.

Authors:  Chi A Ma; Liqiang Xi; Brian Cauff; Adam DeZure; Alexandra F Freeman; Sophie Hambleton; Gary Kleiner; T Ronan Leahy; Maureen O'Sullivan; Michelle Makiya; Grainne O'Regan; Stefania Pittaluga; Julie Niemela; Jennifer Stoddard; Sergio D Rosenzweig; Mark Raffeld; Amy D Klion; Joshua D Milner
Journal:  Blood       Date:  2016-12-12       Impact factor: 22.113

Review 2.  Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.

Authors:  Melanie C Dispenza; Bruce S Bochner
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

3.  Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.

Authors:  Brett King; Alfred Ian Lee; Jaehyuk Choi
Journal:  J Invest Dermatol       Date:  2016-11-22       Impact factor: 8.551

Review 4.  JAK inhibitors in dermatology: The promise of a new drug class.

Authors:  William Damsky; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-01-28       Impact factor: 11.527

Review 5.  Genetics of eosinophilic esophagitis.

Authors:  L C Kottyan; M E Rothenberg
Journal:  Mucosal Immunol       Date:  2017-02-22       Impact factor: 7.313

6.  A novel activating JAK1 mutation in chronic eosinophilic leukemia.

Authors:  William Shomali; Alisa Damnernsawad; Talent Theparee; David Sampson; Quinlan Morrow; Fei Yang; Sebastian Fernandez-Pol; Richard Press; James Zehnder; Jeffrey W Tyner; Jason Gotlib
Journal:  Blood Adv       Date:  2021-09-28

Review 7.  Incomplete penetrance in primary immunodeficiency: a skeleton in the closet.

Authors:  Conor Gruber; Dusan Bogunovic
Journal:  Hum Genet       Date:  2020-02-17       Impact factor: 4.132

8.  CaMKIIδ is upregulated by pro-inflammatory cytokine IL-6 in a JAK/STAT3-dependent manner to promote angiogenesis.

Authors:  Brendan J O'Brien; Harold A Singer; Alejandro P Adam; Roman G Ginnan
Journal:  FASEB J       Date:  2021-04       Impact factor: 5.191

9.  Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid-coated Layer-by-Layer Nanoparticles.

Authors:  Isidora Tošić; Lisa N Heppler; Susana P Egusquiaguirre; Natalie Boehnke; Santiago Correa; Daniel F Costa; Elizabeth A Grossman Moore; Sharmistha Pal; Douglas S Richardson; Alexander R Ivanov; Daphne A Haas-Kogan; Daniel K Nomura; Paula T Hammond; David A Frank
Journal:  Mol Cancer Ther       Date:  2021-02-03       Impact factor: 6.009

Review 10.  Mitochondrial Stat3, the Need for Design Thinking.

Authors:  Rui Yang; Mercedes Rincon
Journal:  Int J Biol Sci       Date:  2016-02-29       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.